Targeting TNF- to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy
about
Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patientsSystemically Administered, Target Organ-Specific Therapies for Regenerative MedicineAdoptive T-cell therapy for cancer: The era of engineered T cellsApproaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cellsWays to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytesUnderstanding high endothelial venules: Lessons for cancer immunologyTargeting the tumor vasculature to enhance T cell activityT cell exclusion, immune privilege, and the tumor microenvironmentOrchestration of angiogenesis by immune cellsCancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination.A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma.Self-targeting of TNF-releasing cancer cells in preclinical models of primary and metastatic tumorsSystemic TNFα gene therapy synergizes with liposomal doxorubicine in the treatment of metastatic cancer.NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells.Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabineControl of the adaptive immune response by tumor vasculature.Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example.Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer.Regulation of cytotoxic T-Lymphocyte trafficking to tumors by chemoattractants: implications for immunotherapy.Exploiting cytokines in adoptive T-cell therapy of cancer.Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART).Adoptive T-Cell Therapy for Solid Tumors.Homing to solid cancers: a vascular checkpoint in adoptive cell therapy using CAR T-cells.Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers.Antitumor activity of TNF-α after intratumoral injection using an in situ thermosensitive hydrogel.High Endothelial Venules and Other Blood Vessels: Critical Regulators of Lymphoid Organ Development and FunctionFine-Tuning Tumor Endothelial Cells to Selectively Kill Cancer.Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma.Won't you come on in? How to favor lymphocyte infiltration in tumors.The tumor vessel targeting agent NGR-TNF controls the different stages of the tumorigenic process in transgenic mice by distinct mechanisms.Intratumoral TNFα improves immunotherapy.Improving drug uptake and penetration into tumors: current and forthcoming opportunities.Preclinical and clinical aspects of TNF-α and its receptors TNFR1 and TNFR2 in breast cancer.Tertiary Lymphoid Structures in Cancer: Drivers of Antitumor Immunity, Immunosuppression, or Bystander Sentinels in Disease?Synergy effects of Polyinosinic-polycytidylic acid, CpG oligodeoxynucleotide, and cationic peptides to adjuvant HPV E7 epitope vaccine through preventive and therapeutic immunization in a TC-1 grafted mouse model.T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.Defining the role of the tumor vasculature in antitumor immunity and immunotherapy.Mechanisms regulating T-cell infiltration and activity in solid tumors.TNF-α promotes colon cancer cell migration and invasion by upregulating TROP-2.A Task Force Against Local Inflammation and Cancer: Lymphocyte Trafficking to and Within the Skin
P2860
Q24633820-A65A6207-3234-4D30-9718-658ED53092C3Q26782082-DAD2E767-9661-4AA2-8A9F-5D00F60D33D1Q26800611-7C71E13F-E413-46C5-A8F5-9B8B37B45951Q26852287-23D2F9EF-7E0E-4A68-A50F-168227EBAC91Q26991991-ACD7B1E2-7383-420C-AD1A-BC082B06C8F7Q27005794-BF01474B-BF5A-4E98-A24D-380A1AB5C6CCQ27026329-A319A7F5-8638-408E-85B8-A88E00B62720Q28259872-E02139E6-C530-48E6-9692-228D1BB7A959Q28389236-14CCA768-0C59-41DD-9732-E1F01567B745Q33954123-B12F76F2-5441-49ED-A10B-F05DF2D9118DQ35201915-3A08CA38-6A3E-4C0C-BD89-B8E1EE09B845Q36646454-EB12863A-D0DA-46B6-8902-4A6E1C98F2D5Q36673686-A44DFF50-0612-43F9-9735-238F4A622916Q37043370-38C9771E-E158-415C-B59E-E9323154E9DCQ37236248-DABEC86A-C089-46B4-9010-AC1AAA6E2C1BQ37683575-71FDEF0D-7E09-4920-94BD-DCDA3A9DC381Q38112578-1830FA5C-8E75-4E4E-A177-5328317D5776Q38151193-5BCBD4BE-FDBF-4D11-9DD5-DE2CBFA5CAB3Q38284345-58DEBF2A-97A3-48E9-BCDD-81D850CFF469Q38525044-83DFEEEF-3937-4101-875C-796B8A26B12BQ38681083-42309DC5-8F46-4006-B6D8-E065FBA444BEQ38754498-B0D34EB1-14BB-420A-8EFA-72AD88F72995Q38805749-178F7AEB-5BFA-4BBC-B5D1-BA399E8A3E33Q38872869-474A0406-A22C-4FDD-9989-77881FC820ACQ39055379-F510D7F1-ED7E-430B-849D-D205EC7F2455Q39143550-741E1EE5-0E90-48B4-B69A-E584B0B5835AQ39406918-351C8D37-D745-4274-BCF3-F59986E6E99FQ40674940-6054F838-8766-4C2C-88B1-EF2BE4A17F6EQ41474524-9BDB51D1-F5DB-4151-A829-3C575082824EQ41577994-8235E63C-67C3-4775-97B6-17ADDE4D9936Q41767601-EBE1D6B6-5514-4F8C-8A10-67C33B8ED79DQ41861892-E40FCC01-CA41-4537-88D3-6B5897B66D09Q47156631-DD1860AA-AF87-4959-A440-45B684BB13D2Q47194123-92B53D82-A386-417C-816F-B498F44D94A9Q47224779-0A7D2F8D-428A-45AB-A055-C625780C42B7Q47570404-4889AE35-5BF4-4F27-ADA0-52E3B9992F43Q49679692-04B3CE7D-79C3-4593-8093-6D685616BDE8Q50089395-78C03B99-3C20-4E89-94C1-9EEB40FF8765Q50214360-99EADE60-9676-4C51-B9D1-A8722CED7FE3Q58566631-E0F37BC1-1A48-44E7-AE6A-595964D5F238
P2860
Targeting TNF- to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy
description
im Februar 2012 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 08 February 2012
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 2012
@uk
name
Targeting TNF- to Neoangiogeni ...... tic Potential of Immunotherapy
@en
Targeting TNF- to Neoangiogeni ...... tic Potential of Immunotherapy
@nl
type
label
Targeting TNF- to Neoangiogeni ...... tic Potential of Immunotherapy
@en
Targeting TNF- to Neoangiogeni ...... tic Potential of Immunotherapy
@nl
prefLabel
Targeting TNF- to Neoangiogeni ...... tic Potential of Immunotherapy
@en
Targeting TNF- to Neoangiogeni ...... tic Potential of Immunotherapy
@nl
P50
P356
P1476
Targeting TNF-α to neoangiogen ...... tic potential of immunotherapy
@en
P2093
Giorgio Parmiani
Matteo Grioni
P304
P356
10.4049/JIMMUNOL.1101877
P407
P577
2012-02-08T00:00:00Z